The comeback story of belantamab mafodotin (Blenrep) hit a roadblock Thursday as the FDA's Oncologic Drugs Advisory Committee ...

The FDA’s approval of linvoseltamab for adults with heavily pretreated relapsed/refractory multiple myeloma marks a significant advance, with Sundar Jagannath, MBBS, emphasizing its high response ...

However, yesterday GSK announced that the FDA has extended the review period for Blenrep to give the agency time to review additional materials submitted by the company, suggesting the company may ...

Multiple myeloma is predominantly a disease of the elderly, with the median age at diagnosis about 70; one-third of patients ...

The FDA's ODAC voted that the benefit-risk profile of belantamab mafodotin in multiple myeloma were not favorable, ...

Novel drug regimens, autologous stem cell transplant (ASCT), and modern supportive care are prolonging remission, improving ...

Bristol Myers’ BMY legacy portfolio comprises Eliquis, Revlimid, Pomalyst, Sprycel and Abraxane. Revenues for the Legacy Portfolio plunged 20% in the first quarter to $5.64 billion due to the ...

Medically reviewed by Archana Sharma, DO There are several treatment options for multiple myeloma. Since this disease varies by person, the type of therapy you receive depends on factors such as your ...

Mantle cell lymphoma treatment offers options if patients relapse after CAR T-cell therapy, from bispecific antibodies, antibody drug conjugates, and other emerging therapies.

BMY is already facing top-line pressure as the legacy portfolio is under pressure due to continued generic impact on Revlimid, Pomalyst, Sprycel and Abraxane.